07:00 , Mar 28, 2016 |  BioCentury  |  Finance

Back in the game

After spending the last few years exiting many of its biotech portfolio companies, Gimv is again putting capital to work in the space. The firm is picking up where it left off with a bet...
08:00 , Feb 22, 2016 |  BioCentury  |  Finance

Fixing fibrosis

The combination of new mechanistic insights into how to modulate IPF and regulatory clarity around the disease convinced Third Rock Ventures to form a company focused on therapeutics that can halt and reverse fibrosis. The...
01:51 , Feb 19, 2016 |  BC Extra  |  Financial News

Third Rock fibrosis play debuts with $45M

Third Rock Ventures launched fibrosis company Pliant Therapeutics Inc. (Redwood City, Calif.) with a $45 million series A round. The biotech is developing a small molecule inhibitor of integrin alpha(V)beta(1) ( CD51/CD29 ) to treat...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

ActoGeniX, Intrexon deal

Synthetic biology company Intrexon will acquire ActoGeniX for $60 million, comprising $30 million in cash and $30 million in stock. Intrexon will gain ActoGeniX’s TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms....
02:03 , Feb 14, 2015 |  BC Extra  |  Company News

Intrexon acquires mucosal therapeutics play ActoGeniX

Synthetic biology company Intrexon Corp. (NYSE:XON) will acquire ActoGeniX N.V. (Zwijnaarde, Belgium) for $60 million. Intrexon will gain ActoGeniX's TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms, and a pipeline including two...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

AG014: Phase I data

An open-label, Belgian Phase I trial in healthy volunteers showed that oral AG014 was well tolerated. Pharmacokinetic data showed that AG014 bacteria were released at the targeted gastrointestinal regions, including the small and large intestines,...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Gut reaction

Gut reaction Synlogic Inc. is using its $29.4 million series A round to develop engineered microbes that could enable more fine-tuned delivery of therapeutic proteins than other bacterial delivery platforms, as well as have a...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

ActoGeniX, Stallergenes deal

The companies partnered to develop allergy treatments using ActoGeniX's ActoBiotics mucosal delivery technology. ActoGeniX will develop clinical ActoBiotic candidates that express undisclosed predefined allergens. After the end of a proof-of-concept study, Stallergenes will have an...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Financial News

ActoGeniX completes venture financing

ActoGeniX N.V. , Zwijnaarde, Belgium   Business: Drug delivery   Date completed: 4/18/13   Type: Venture financing   Raised: €10.7 million ($14 million)   Investors: Saffelberg Investments; company founders; existing investors  ...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

ActoGeniX, Merck deal

ActoGeniX said it partnered with Merck to develop and validate an antibody therapy for an undisclosed indication using ActoGeniX's ActoBiotics drug delivery technology. ActoBiotics are oral capsules of Lactococus lactis bacteria that have been genetically...